Showing 7231-7240 of 10469 results for "".
- Concern About Zika Virus in US Set to Escalatehttps://practicaldermatology.com/news/concern-about-zika-virus-in-us-set-to-escalate/2458751/U.S dermatologists may start to receive calls from patients who are concerned about infection with Zika virus – particularly pregnant ones. Zika is now spreading rapidly across Latin America and the Caribbean. So far, one case has been identified in Houston, but the possibility
- Study Highlights Risk Factors for cSCC Recurrence, Metastasis and Deathhttps://practicaldermatology.com/news/study-highlights-risk-factors-for-cscc-recurrence-metastasis-and-death/2458753/Tumor depth confers the highest risk of local recurrence and metastasis of cutaneous squamous cell carcinoma (cSCC) and tumor diameter exceeding 20 mm is associated with the highest risk for disease-specific death, a new study suggests. The findings are published online in
- Study: With Botox 'Chemodenervation,' Dermal Fillers Last Longerhttps://practicaldermatology.com/news/study-with-botox-chemodenervation-dermal-fillers-last-longer/2458757/Experimental evidence supports a simple technique for prolonging the effects of Hyaluronic acid (HA) dermal fillers: using them together with botulinum toxin, according to a study published in the January issue of Plastic and
- AADA Provides Input on Skin Cancer Screening Recommendationhttps://practicaldermatology.com/news/aada-provides-input-on-skin-cancer-screening-recommendation/2458761/Recognizing the importance of early detection, the American Academy of Dermatology Association (AADA) has responded to the U.S. Preventive Services Task Force Draft Recommendation Statem
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- ASDS Honors Dr. Ian Maher for Outstanding Servicehttps://practicaldermatology.com/news/asds-honors-dr-ian-maher-for-outstanding-service/2458764/The American Society for Dermatologic Surgery (ASDS) last month presented Ian A. Maher, MD, of St. Louis with the ASDS Award for Outstanding Service. The award is given annually to one member who has volunteered his or her time for multiple Society projects or initiatives. In an effort to recogni
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- New Rosacea Research Findings Presented During SID Annual Meetinghttps://practicaldermatology.com/news/new-rosacea-research-findings-presented-during-sid-annual-meeting/2458777/Medical scientists reviewed research on the microbiome, genetics and pathophysiology of rosacea and presented results of new studies funded by the National Rosacea Society (NRS) during its research workshop at the Society for Investigative Dermatology annual meeting. “Research suppo
- Strathspey Crown Appointments Murthy Simhambhatla, PhD, as Senior Partnerhttps://practicaldermatology.com/news/strathspey-crown-appointments-murthy-simhambhatla-phd-as-senior-partner/2458776/Strathspey Crown Holdings LLC announced the appointment of Murthy Simhambhatla, PhD as a Senior Partner of the firm. Dr. Simhambhatla has more than 20 years of experience in bioscience and has built a successful track record in the healthcare industry. Dr. Simhambhatla was